Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300 mg)

Triumeq a new single tablet regimen (STR), combining abacavir 600mg, dolutegravir 50mg and lamivudine 300 mg has been approved by the Therapeutic Goods Administration (TGA) in Australia. It is manufactured by ViiV Healthcare and is already available in the US (Aug 2014) and European Union (Sept 2014). It is the first single-tablet regime that does […]